Terrie Curran - Jan 19, 2023 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role: President and Chief Executive, Director
Signature: /s/ Larry Miller, Attorney-in-Fact for Terrie Curran
Stock symbol: PHAT
Transactions as of: Jan 19, 2023
Transactions value $: -$47,729
Form type: 4
Date filed: 1/20/2023, 06:39 PM
Previous filing: Nov 23, 2022
Next filing: Mar 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHAT	Common Stock	Award	$0	+97.5K	+114.53%	$0.00	183K	Jan 19, 2023	Direct	F1, F2
transaction	PHAT	Common Stock	Sale	-$47.7K	-5.82K	-3.19%	$8.20	177K	Jan 20, 2023	Direct	F3
holding	PHAT	Common Stock						2.24K	Jan 19, 2023	by 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PHAT	Stock Option (Right to Buy)	Award	$0	+163K		$0.00	163K	Jan 19, 2023	Common Stock	163K	$8.35	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2	Includes 1,408 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023.
F3	Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.16 to $8.20. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.